-
-
-
-
-
-
-
Sumitovant Biopharma, Sumitomo Pharma, and Myovant Sciences Enter into Definitive Agreement
-
-
-
-
-
-
-
Myovant Sciences Special Committee of Board Confirms Receipt of Preliminary, Non-binding Proposal from Sumitovant Biopharma and Sumitomo Pharma to Acquire Remaining Shares
-
-
-
-
-
-
-
Myovant Sciences and Pfizer Announce Publication in The Lancet of Phase 3 SPIRIT 1 and SPIRIT 2 Studies of Once-Daily Relugolix Combination Therapy in Women With Endometriosis-Associated Pain
-
-
-
-
-
-
-
Myovant Sciences Announces Corporate Updates and Financial Results for Fourth Fiscal Quarter and Fiscal Year Ended March 31, 2022
-
-
-
-
-
-
-
Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated with Endometriosis
-
-
-
-
-
-
-
Myovant Sciences Announces Preliminary Financial Results for Third Quarter of Fiscal Year 2021
-
-
-
-
-
-
-
Myovant Sciences (MYOV), Pfizer (PFE) Announce FDA Acceptance of sNDA for MYFEMBREE for Management of Moderate to Severe Pain Associated With Endometriosis
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

